Add Company
Join Now

MiNK Therapeutics Revenue and Competitors

License our Company Data API

Boston, MA USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • MiNK Therapeutics's estimated annual revenue is currently $6.7M per year.(i)
  • MiNK Therapeutics's estimated revenue per employee is $155,000

Employee Data

  • MiNK Therapeutics has 43 Employees.(i)
  • MiNK Therapeutics grew their employee count by -10% last year.

MiNK Therapeutics's People

NameTitleEmail/Phone
1
President and CEOReveal Email/Phone
2
Director DiscoveryReveal Email/Phone
3
Director, Translational ResearchReveal Email/Phone
4
Executive Director, Program ManagementReveal Email/Phone
5
Senior Director, Program OperationsReveal Email/Phone
6
Scientist IReveal Email/Phone
7
Scientist IIReveal Email/Phone
8
Associate ScientistReveal Email/Phone
9
Scientist 1Reveal Email/Phone
10
Senior ScientistReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$12.7M82-45%$107.3MN/A
#2
$0.2M1-50%N/AN/A
#3
$6.2M4021%N/AN/A
#4
$42.2M2184%$165MN/A
#5
$14.6M94-37%$312.8MN/A
#6
$0.3M2-67%N/AN/A
#7
$235M366-5%$340.9MN/A
#8
$56M289-7%$7.6MN/A
#9
$4.7M6136%N/AN/A
#10
$2M138%N/AN/A
Add Company

What Is MiNK Therapeutics?

We are a clinical stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells are a distinct T cell population that combine durable memory responses with the rapid cytolytic features of natural killer (NK) cells. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells and suppress Graft versus Host Disease (GvHD). Our proprietary platform is designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. As such, we believe that our approach represents a highly versatile application for therapeutic development in cancer and immune diseases. We have leveraged our platform and manufacturing capabilities to develop a wholly owned pipeline for both native and engineered iNKT cells.

keywords:N/A

N/A

Total Funding

43

Number of Employees

$6.7M

Revenue (est)

-10%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$6M4316%N/A
#2
$10.8M43-34%$179M
#3
$10M4323%N/A
#4
$3.4M43-2%N/A
#5
$10.5M43-7%N/A